Espinoza Octavio, an insider at Ligand Pharmaceuticals Inc (LGND), purchased 28,386 shares of the company's stock on December 15, 2025, at a price of $92.65 per share, amounting to a total transaction value of $2.63 million. Following this acquisition, Octavio holds a total of 28,386 shares in the biopharmaceutical company.
Ligand Pharmaceuticals, headquartered in Jupiter, Florida, develops and acquires technologies that aid pharmaceutical companies in discovering and developing medicines. The company operates two infrastructure-light, royalty-generating IP platform technologies, including the Captisol platform, which has enabled several FDA-approved products. As of November 20, 2025, Ligand Pharmaceuticals has a market capitalization of $4.1 billion and a trailing P/E ratio of 83.48, with an EPS of 2.08.
Insider transactions, such as this acquisition, offer transparency into how executives view their company's stock. While such buying activity can indicate confidence in the company's future, it is important for investors to consider broader patterns of insider trading rather than isolated transactions. Upcoming earnings reports are anticipated, with EPS estimates of $1.89 and $1.92 for the quarters ending August 5, 2026, and May 6, 2026, respectively, alongside revenue estimates of $64.9 million and $61.3 million.